Completed PHASE4 INTERVENTIONAL 2-arm NCT02426944

Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation (PRAGUE-17)

Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)

Sponsor: Charles University, Czech Republic

Conditions Atrial Fibrillation

Interventions Left atrial appendage closure NOAC

Updated 8 times since 2017 Last updated: Jun 9, 2021 Started: Oct 13, 2015 Primary completion: Jul 20, 2019 Completion: Jul 20, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Atrial Fibrillation, this trial is completed. The trial is conducted by Charles University, Czech Republic and has accumulated 8 data snapshots since 2015. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Sep 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE4
Aug 2019 — Jan 2021 [monthly]

Recruiting PHASE4

▶ Show 3 earlier versions

Feb 2019 — Aug 2019 [monthly]

Recruiting PHASE4
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE4
Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE4

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Charles University, Czech Republic
Ministry of Health, Czech Republic

Data source: Charles University, Czech Republic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Prague, Czechia